NCT02813798View on ClinicalTrials.gov

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Renal ImpairmentHealthy
Interventions
DRUG

Rivipansel

A single 840mg dose of Rivipansel over 20 minutes

Trial Locations (3)

32720

Avail Clinical Research, LLC, DeLand

32809

Orlando Clinical Research Center, Orlando

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors
lead

GlycoMimetics Incorporated

INDUSTRY

NCT02813798 - A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects | Biotech Hunter | Biotech Hunter